A phase @ randomized clinical trial was designed to test whether bardoxolone methyl , a nuclear factor erythroid-@-related factor @ ( Nrf@ ) activator , slows progression to end-stage renal disease in patients with stage @ chronic kidney disease and type @ diabetes mellitus .